Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEBBRA study of cetuximab + encorafenib + binimetinib induction therapy in BRAF V600E-mutated MSS resectable or potentially resectable advanced colorectal cancer
2022-502413-29-00Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, encorafenib and binimetinib in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoints: Radical treatment rate, R0/R1 resection or complete tumor destruction rate and 1 more. Started Oct 2023; status: completed.
02
Drugs
cetuximabencorafenibbinimetinib
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-502413-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502413-29-00.